The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor infiltrative pattern predicts sites of recurrence after curative gastrectomy for gastric cancer.
 
Mitsuro Kanda
No Relationships to Disclose
 
Daisuke Kobayashi
No Relationships to Disclose
 
Chie Tanaka
No Relationships to Disclose
 
Suguru Yamada
No Relationships to Disclose
 
Tsutomu Fujii
No Relationships to Disclose
 
Goro Nakayama
No Relationships to Disclose
 
Hiroyuki Sugimoto
No Relationships to Disclose
 
Masahiko Koike
No Relationships to Disclose
 
Michitaka Fujiwara
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Ajinomoto; Bayer; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Merck; MSD; Olympus; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - abbott Japan (Inst); Abbvie (Inst); Ajinomoto (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Covidien (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Japan Blood Products Organization (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Lilly Japan (Inst); Merck (Inst); Mitsubishi Tanabe Pharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Pharmaceutical (Inst); Yoshindo (Inst)